Cigna Group reported second-quarter 2026 adjusted earnings per share (EPS) of $7.78, surpassing the analyst consensus estimate of $7.60 by 2.37 percent. This result represents an 8.06 percent increase over the $7.20 per share recorded in the same period last year. Quarterly sales reached $71.558 billion, exceeding the consensus estimate of $70.339 billion by 1.73 percent and marking a 6.59 percent growth from the $67.134 billion reported in the prior year period. The strong financial performance was primarily driven by Evernorth Health Services and Cigna Healthcare, leading the company to raise its full-year 2026 adjusted earnings guidance to at least $30.45 per share from prior guidance of at least $30.35.

The filing confirms that both key metrics exceeded market expectations, with earnings beating estimates by a wider margin than revenue. While total customer relationships decreased 3 percent to 182.8 million from December 31, 2025, medical customers increased 2 percent to 18.4 million. Conversely, pharmacy customers decreased 4 percent to 118.2 million, reflecting expected client transitions and lower membership from health plan clients. Brian Evanko, President and CEO of Cigna Group, stated that the results demonstrate the effectiveness of their strategy in harnessing technology and data to lower costs.

Financial Performance Overview

The following table outlines the key financial metrics reported by Cigna Group for the quarter compared to analyst estimates and the prior year period:

Adjusted earnings per share rose to $7.78 from $7.20 in the same quarter last year. Sales grew to $71.558 billion from $67.134 billion previously. Both increases reflect double-digit percentage growth in EPS and mid-single-digit growth in revenue on a year-over-year basis.

Segment Results and Medical Care Ratio

Evernorth Health Services adjusted revenues increased 6 percent to $61.468 billion. Within this segment, Pharmacy Benefit Services revenue rose 8 percent to $34.496 billion, while Specialty and Care Services revenue increased 4 percent to $26.972 billion, reflecting strong specialty volume growth. Cigna Healthcare sales increased 9 percent to $11.728 billion, primarily reflecting premium rate increases to cover expected increases in medical costs.

The Medical Care Ratio (MCR) was 84.5 percent for the second quarter of 2026, compared to 83.2 percent a year ago. This increase was primarily due to higher prior-year risk adjustment benefits within the Individual and Family Plans business recognized in the second quarter of 2025. Cigna Healthcare affirmed its full-year MCR guidance to be between 83.7 percent and 84.7 percent.

What the Numbers Show

The divergence between the beat magnitude for earnings versus sales is notable. While sales exceeded estimates by 1.73 percent, adjusted EPS beat expectations by 2.37 percent. This suggests that operating leverage or margin expansion contributed to the earnings outperformance relative to the top-line surprise. Additionally, the 8.06 percent year-over-year growth in EPS outpaced the 6.59 percent growth in sales, indicating that profitability improved at a faster rate than revenue expansion during the period.

Ann Dennison, Cigna EVP and CFO, highlighted a shift in prescription trends, noting that GLP-1 drug utilization growth trended down from elevated levels experienced in prior periods as coverage levels slightly declined. She expects this trend to continue throughout the remainder of the year, a factor already contemplated in the company’s full-year outlook. Despite the stock dropping 2.05 percent to $290.39 following the report, the raised guidance signals management’s confidence in maintaining momentum despite moderating specialty drug growth.

Cigna Group (NYSE: CI) is projected to deliver adjusted earnings per share (EPS) exceeding $30.45 for fiscal year 2026, surpassing the consensus estimate of $30.41. The positive variance suggests stronger-than-anticipated profitability for the healthcare services provider in the upcoming reporting period.

The expectation reflects a beat against analyst forecasts, with the projected figure standing at more than $30.45 compared to the $30.41 estimate. This margin of improvement highlights investor confidence in the company’s financial performance for the full year.

Financial Projections

What the Numbers Show

The data indicates a clear outperformance relative to market expectations. With the adjusted EPS forecast rising above the $30.41 benchmark, Cigna Group demonstrates resilience in its earnings generation capabilities for FY2026.